prostate cancer treatment - Orion receives European rights from Indevus for Vantas(R), for … - Trading Markets (press release)

Histrelin, the active ingredient in Vantas, is a luteinizing hormone-releasing hormone (LHRH) agonist administered via a 12-month implant utilising Indevus patented polymer technology. A Mutual Recognition Procedure for European approvals is currently under way in several countries, based on the marketing authorisation granted by Denmark. Orion will pay Indevus an up-front payment of USD 7 million. Later payments, the total of which can be up to USD 14 million, are conditional and related to marketing approvals and sales thresholds. Orion is a European pharmaceutical and diagnostics company which emphasises the development of innovative medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets pharmaceuticals for humans and animals, active pharmaceutical ingredients as well as diagnostic tests. read more

Tags: tradingmarkets, european, prostate cancer cures, prostate cancer questions and answers, indevus, Prostate surgery, prostate cancer statistics